基于神经成像的药物发现,用于阿尔茨海默病中的粉样蛋白清除疗法,使用验证的因果关系分析
Anindita Bhattacharjee1, Pratik Purohit1, Prasun K Roy2
1School of Bio-Medical Engineering, Indian Institute of Technology (B.H.U.), Varanasi 221005, India.
Psychiatry research. Neuroimaging
|November 3, 2024
概括
阿尔茨海默病 (AD) 患者的低胆酸水平与粉样质斑块增加和脑血流减少有关. 这表明胆酸衍生物可能是阿尔茨海默病的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
- 生物化学 生物化学
背景情况:
- 衰老会损害肝功能,影响胆固醇代谢,减少大脑胆固醇酸 (CA) 的可用性.
- 临床前研究表明,CA具有与阿尔茨海默病 (AD) 相关的神经保护性质.
研究的目的:
- 在阿尔茨海默病中调查粉样β,胆酸和脑血流之间的因果关系.
- 探索针对AD中这些途径的治疗潜力.
主要方法:
- 在健康人群和AD患者中测量了血清CA水平.
- 使用MRI-ASL和PET-AV45扫描分别评估了脑血流 (CBF) 和粉样β负载.
- 使用计算因果连接分析来确定因果关系.
主要成果:
- 与对照组相比,AD患者的血清CA水平显著降低.
- 因果分析显示,降低CA会增加粉样蛋白负载,而增加粉样蛋白负载会降低CBF.
- 这些发现得到了临床前证据的支持,这些证据将CA与减少粉样蛋白形成和改善血管功能联系起来.
结论:
- 减少胆酸与阿尔茨海默病中粉样蛋白负担增加和大脑血流受损有因果关系.
- 使用胆酸盐衍生物的药理学调制为AD提供了潜在的新型治疗策略.
- 这项研究提供了一个基于神经成像的理由,用于探索在AD治疗中基于胆酸的干预措施.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.6K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449